No Data
Silo Pharma Shares Are Trading Lower After the Company Completed a Pre-investigational New Drug Meeting With the FDA for SPOC-15, an Intranasal Prophylactic Treatment for PTST and Stress-induced Anxiety Disorder.
Silo Pharma Outlines Strategic Direction and Innovative Pipeline
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
Express News | Silo Pharma Announces Completion of FDA Pre-Ind Meeting to Advance Development of Spc-15 for Treatment of Ptsd
Silo Pharma Files for Secondary Stock Offering
Silo Pharma Shares Jump 11% on Ketamine-Treatment Partnership
No Data
No Data
